Revamped Purple Book Offers Greater Patent Transparency for Biologics

The Purple Book—a database containing information about all licensed biological products—is set for a revamping that offers more patent transparency regarding reference biologics. The Purple Book, which was first published in 2014, a year before the 2015 approval of the first biosimilar product ......
By: Morgan Lewis - As Prescribed

Array